Type 2 Diabetes | Current Treatment | EU5 | 2017

The type 2 diabetes market is expanding rapidly, fueled by increasing prevalence and a wave of recent product launches. Sanofi’s Suliqua (lixisenatide/insulin glargine), Novo Nordisk’s Fiasp, and AstraZeneca’s Glyxambi (linagliptin/empagliflozin) are examples of recent European product approvals. DRG believes the positive results from the EMPA-REGCVOT for Boehringer Ingelheim’s/Eli Lilly’s Jardiance will benefit uptake of the entire SGLT-2 inhibitor class. Current Treatment explores how the prescribing behaviors of European endocrinologists have changed in response to the rise of the SGLT-2 inhibitors and how other novel drugs compare.

Login to access report

launch Related Market Assessment Reports